XOMA to Present at the Canaccord Adams 26th Annual Summer Seminar on August 8, 2006
Friday July 28, 4:35 pm ET
BERKELEY, Calif.--(BUSINESS WIRE)--July 28, 2006--XOMA Ltd. (Nasdaq:XOMA - News) announced today that David Boyle, XOMA's Chief Financial Officer, and Dr. Robert Gundel, XOMA's Vice President for Scientific Corporate Development, will present an overview of XOMA's business strategy and update of the company's pipeline and collaborations at the Canaccord Adams 26th Annual Summer Seminar on Tuesday, August 8 at 2:30 pm local time at the Boston Marriott Long Wharf Hotel in Boston, Massachusetts. In addition, Dr. Gundel will participate in a panel discussion entitled "Accelerated Approval for Oncology Drugs -- A Useful Tool?" to be held during the lunch session on August 8 from noon to 12:55 p.m. in the New York City Room.
ADVERTISEMENT
XOMA's corporate presentation will be followed immediately by a breakout question and answer session. Parties interested in scheduling one-on-one meetings with XOMA's executives are invited to contact Rachel Allaire at Rachel.allaire@canaccordadams.com. An audio webcast of the presentation will be available live at www.corporate-ir.net/ireye/conflobby.zhtml?ticker=XOMA&item_id=1351844
An archived version of the webcast will be available at this web address for 90 days following the presentation.
About XOMA
XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA® (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(TM) (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech and Novartis AG) to treat neovascular (wet) age-related macular degeneration. |
